Porto Conte Ricerche Srl, Tramariglio, Alghero, Sassari, Italy.
Amino Acids. 2012 Oct;43(4):1499-507. doi: 10.1007/s00726-012-1223-0. Epub 2012 Jan 26.
Lipid-lowering therapy has been reported to reduce several oxidative stress (OS) markers in hypercholesterolemia. Since OS is frequently associated with renal dysfunction, we aimed to investigate the effect of hypolipidemic drugs on oxidative stress and plasma taurine (Tau), a sulfur amino acid with a marked antioxidant effect, in chronic kidney disease (CKD). We enrolled 30 CKD randomized to receive three different hypolipidemic regimens for 12 months: simvastatin alone (40 mg/day) or ezetimibe/simvastatin combined therapy (10/20 or 10/40 mg/day). Low molecular weight (LMW) thiols including homocysteine, cysteine, cysteinylglycine, glutathione, and glutamylcysteine in their reduced and total form and oxidative stress indices as malondialdehyde (MDA) and allantoin/uric acid (All/UA) ratio were also evaluated. Tau concentration significantly increased throughout the therapy. The rise of taurine was more striking for the group with the concomitant administration of ezetimibe/simvastatin 10/40 mg/day (+31.6% after 1 year of therapy). A significant decrease of both MDA and All/UA ratio was observed during therapy for all patients (-19% for both MDA and All/UA ratio) with a more pronounced effect in patients treated with ezetimibe/simvastatin 10/40 mg/day (-26% for MDA and -28% for All/UA ratio). Besides, an increase of thiols reduced forms was found (+20.7% of LMW thiols redox status) with a greater effect in subjects treated with ezetimibe/simvastatin 10/40 mg/day (+24.7%). Moreover, we demonstrated that oxidative stress improvement during therapy was correlated with increased taurine levels. We hypothesize that taurine may be responsible for the oxidative stress improvement observed during lipid-lowering treatment through the reduction of superoxide anion production at the respiratory chain activity level.
降脂治疗已被报道可降低高胆固醇血症中的几种氧化应激（OS）标志物。由于 OS 常与肾功能障碍相关，我们旨在研究降脂药物对慢性肾脏病（CKD）患者氧化应激和血浆牛磺酸（Tau）的影响，Tau 是一种具有显著抗氧化作用的含硫氨基酸。我们招募了 30 名 CKD 患者，他们随机接受三种不同的降脂治疗方案，为期 12 个月：单独辛伐他汀（40 mg/天）或依折麦布/辛伐他汀联合治疗（10/20 或 10/40 mg/天）。还评估了低分子量（LMW）硫醇，包括还原和总形式的同型半胱氨酸、半胱氨酸、半胱氨酰甘氨酸、谷胱甘肽和谷氨酰半胱氨酸，以及氧化应激指标丙二醛（MDA）和尿酸/尿囊素（All/UA）比值。牛磺酸浓度在整个治疗过程中显著增加。依折麦布/辛伐他汀 10/40 mg/天联合治疗组的牛磺酸升高更为显著（治疗 1 年后增加 31.6%）。所有患者的 MDA 和 All/UA 比值均在治疗期间显著下降（MDA 和 All/UA 比值均下降 19%），依折麦布/辛伐他汀 10/40 mg/天治疗的患者下降更为明显（MDA 下降 26%，All/UA 比值下降 28%）。此外，还发现 LMW 硫醇还原形式增加（LMW 硫醇氧化还原状态增加 20.7%），依折麦布/辛伐他汀 10/40 mg/天治疗的患者增加更为明显（增加 24.7%）。此外，我们还证明了治疗过程中氧化应激的改善与牛磺酸水平的升高有关。我们假设牛磺酸可能通过降低呼吸链活性水平的超氧阴离子生成来负责降脂治疗过程中观察到的氧化应激改善。
